Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML Ended

2023-508655-39-00 Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic 7 2019-02-13
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread Ended

2023-508207-21-00 Advanced Malignant Tumors 9 2019-02-08
Phase II Open Labeled Trial of Disulfiram with Copper in Metastatic Breast Cancer Ended

2024-514665-19-00 metastatic breast cancer 4 2019-01-29
Phase 1 / 2 study of amcenestrant (SAR439859) single agent and in combination with other anti-cancer therapies in postmenopausal women with … Ended

2024-512997-89-00 Cancer 7 2019-01-29
Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma Ended

2023-508343-48-00 Adult patients with relapsed or refractory aggressive B 5 2019-01-25
Efficacy and safety of tisagenlecleucel in adult patients with refractory or relapsed follicular lymphoma Ended

2023-508127-13-00 Adult patients with refractory or relapsed follicular l 4 2019-01-25
Study of efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated l… Ended

2024-511490-29-00 Non-small cell lung cancer 5 2019-01-24
A study of full treatment-free remission in patients with chronic myeloid leukemia Ended

2024-516122-66-00 Chronic myeloid leukemia 4 2019-01-18
Study of subcutaneous nivolumab monotherapy with or without Recombinant Human Hyaluronidase PH20 (rHuPH20) Ended

2023-503554-12-00 lung cancer; kidney cancer; melanoma; liver cancer; col 9 2019-01-09
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin… Ended

2024-513513-12-00 Cholangiocarcinoma 5 2019-01-06
A study to assess the efficacy and safety of bb2121 in people who have Myeloma that is not responsive after treatment or who had Myeloma whi… Ended

2023-505183-10-00 Relapsed and refractory multiple myeloma (RRMM), multip 4 2019-01-04
A clinical study to investigate if the investigational products, called LN-144 and LN-145 (also known as Tumour Infiltrating Lymphocytes), a… Ended

2024-510779-39-00 Neoplasm 4 2018-12-19
A Study of Pembrolizumab Combination Therapy for Advanced Non-Small Cell Lung Cancer Ended

2022-500990-16-00 Stage IV non-small cell lung cancer 4 2018-12-19
First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended

2022-502124-52-00 Advanced epithelial ovarian cancer 5 2018-12-18
Olaparib Monotherapy in HRRm or HRD Positive Cancer Ended

2022-500797-34-00 Treatment of participants with positive cancer for HRRm 4 2018-12-17
A study of Chemo only versus Chemo plus Nivo with or without BMS986205, Followed by Post- Surgery Therapy with Nivo or Nivo and BMS986205 in… Ended

2024-512158-12-00 Bladder Cancer Muscle-Invasive Bladder Cancer 5 2018-12-14
Combination of Talimogene Laherparepvec (modified Herpes Virus) with atezolizumab (monoclonal antibody) in patients with residual breast can… Ended

2023-508550-25-00 Pre and post-menopausal women with resectable primary b 3 2018-12-10
Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinoma Ended

2023-508890-10-00 Gastric and gastric esophageal junction (GEJ) adenocarc 5 2018-12-05
Study of efficacy and safety of asciminib in addition to imatinib in CML-CP patients without a deep level or response on imatinib Ended

2024-515040-23-00 Chronic Myelogenous Leukemia in chronic phase (CML-CP), 4 2018-11-26
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimum… Ended

2023-509061-20-00 Advanced solid tumors 9 2018-11-22
First line treatment with osimertinib in non-small cell lung cancer, coupled with studies on biological samples. Ended

2024-513881-20-00 EGFR-mutated non-small cell lung cancer 4 2018-11-19
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamet… Ended

2023-507312-13-00 Multiple Myeloma 5 2018-11-15
A Phase II trial find out the effectiveness and safety of durvalumab combined with olaparib compared to durvalumab alone, in treating patien… Ended

2024-512769-16-00 Stage IV Non Small Cell Lung Cancer whose tumors lack E 4 2018-11-14
Clinical Trial conduct to investigate if Daratumumab therapy for multiple myeloma patients with minimal residual disease (MRD) reappearance … Ended

2024-518400-50-00 Multiple Myeloma and Minimal Residual Disease 4 2018-11-14